AU768796B2 - Capsule system - Google Patents
Capsule system Download PDFInfo
- Publication number
- AU768796B2 AU768796B2 AU37266/00A AU3726600A AU768796B2 AU 768796 B2 AU768796 B2 AU 768796B2 AU 37266/00 A AU37266/00 A AU 37266/00A AU 3726600 A AU3726600 A AU 3726600A AU 768796 B2 AU768796 B2 AU 768796B2
- Authority
- AU
- Australia
- Prior art keywords
- capsule
- active agent
- capsule system
- vehicle
- triglyceride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002775 capsule Substances 0.000 title claims description 66
- 239000013543 active substance Substances 0.000 claims description 39
- 239000003981 vehicle Substances 0.000 claims description 32
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical group N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 28
- 229960000565 tazarotene Drugs 0.000 claims description 28
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003995 emulsifying agent Substances 0.000 claims description 16
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 16
- 238000012384 transportation and delivery Methods 0.000 claims description 15
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 13
- 239000007957 coemulsifier Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 10
- 239000001593 sorbitan monooleate Substances 0.000 claims description 10
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 10
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 10
- 238000004945 emulsification Methods 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 5
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- 229960004716 idoxuridine Drugs 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 description 14
- 239000008273 gelatin Substances 0.000 description 14
- 229920000159 gelatin Polymers 0.000 description 14
- 235000019322 gelatine Nutrition 0.000 description 14
- 235000011852 gelatine desserts Nutrition 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 7
- -1 for example Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960005339 acitretin Drugs 0.000 description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
- 229960002199 etretinate Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/262,623 US6248354B1 (en) | 1999-03-04 | 1999-03-04 | Capsule system |
| US09/262623 | 1999-03-04 | ||
| PCT/US2000/005811 WO2000051571A2 (en) | 1999-03-04 | 2000-03-03 | Capsule system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3726600A AU3726600A (en) | 2000-09-21 |
| AU768796B2 true AU768796B2 (en) | 2004-01-08 |
Family
ID=22998308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU37266/00A Ceased AU768796B2 (en) | 1999-03-04 | 2000-03-03 | Capsule system |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6248354B1 (https=) |
| EP (1) | EP1158965A2 (https=) |
| JP (1) | JP2002538098A (https=) |
| AU (1) | AU768796B2 (https=) |
| CA (1) | CA2363933C (https=) |
| HK (1) | HK1042241A1 (https=) |
| WO (1) | WO2000051571A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248354B1 (en) * | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
| US7115277B2 (en) * | 1999-03-04 | 2006-10-03 | Allergan, Inc. | Method for enabling delivery of an active agent |
| US6457471B1 (en) | 2000-06-30 | 2002-10-01 | Medihale Ltd. | Dual-purpose medical device for upper airway treatment and methods for using same |
| KR100560092B1 (ko) * | 2000-12-15 | 2006-03-10 | 파트릭 프랑케 | 저알레르기성 및 비자극성 피부 보호 제제 |
| US6752953B2 (en) * | 2001-12-03 | 2004-06-22 | Yung Shin Pharmaceutical Co., Ltd. | Method for manufacturing hard non-gelatin pharmaceutical capsules |
| EP1547588B1 (en) * | 2002-08-20 | 2013-12-11 | Kowa Company, Ltd. | Soft capsule preparation |
| EP1527774A1 (en) * | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
| US20050026958A1 (en) * | 2003-07-30 | 2005-02-03 | Allergan, Inc. | Methods of therapeutic treatment using amounts of retinoid components |
| US20050026950A1 (en) * | 2003-07-30 | 2005-02-03 | Allergan, Inc. | Methods of therapeutic treatment using retinoids to achieve consistent bioavailability |
| CA2534008A1 (en) * | 2003-07-30 | 2005-02-10 | Allergan, Inc. | Methods of therapeutic treatment using amounts of retinoid components |
| US20050026949A1 (en) * | 2003-07-30 | 2005-02-03 | Allergan, Inc. | Methods of therapeutic treatment using amounts of retinoids without regard to body weight |
| US20060020037A1 (en) * | 2004-07-22 | 2006-01-26 | Allergan, Inc. | Tazarotenic acid and esters thereof for treating autism |
| US20060234948A1 (en) * | 2005-04-04 | 2006-10-19 | Empie Mark W | Lignan-containing compositions |
| US20070060620A1 (en) * | 2005-09-09 | 2007-03-15 | John Sefton | Use of RAR retinoid agonists to increase sperm count and sperm mobility in males |
| CN102438590B (zh) * | 2009-02-25 | 2013-07-10 | 施泰福研究澳大利亚有限公司 | 局部泡沫组合物 |
| US10022348B2 (en) | 2009-05-20 | 2018-07-17 | Sun Pharmaceutical Industries Limited | Topical solution of isotretinoin |
| EP3006021A1 (en) | 2009-05-20 | 2016-04-13 | Ranbaxy Laboratories Limited | Topical retinoid solutions |
| GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| BR112014032948A2 (pt) * | 2012-07-02 | 2017-06-27 | Dsm Ip Assets Bv | cápsulas contendo timoquinona |
| JP7728653B2 (ja) * | 2021-04-05 | 2025-08-25 | 真 小林 | 内視鏡用処置具 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0184942A2 (en) * | 1984-12-14 | 1986-06-18 | Ortho Pharmaceutical Corporation | Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient |
| US4612194A (en) * | 1984-02-15 | 1986-09-16 | Roshdy Ismail | Anti-rheumatic agents and their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960M (fr) * | 1962-03-30 | 1964-11-30 | Pfizer & Co C | Compositions, facilement dispersibles dans l'eau, a base d'ester d'acide gras de vitamine a. |
| JPS58128141A (ja) * | 1982-01-26 | 1983-07-30 | Sumitomo Chem Co Ltd | 自己乳化分散型カロチノイド類含有ソフトカプセル剤の製法 |
| GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| JPH0426670A (ja) * | 1990-05-18 | 1992-01-29 | Nisshin Flour Milling Co Ltd | 安定化された油溶性ビタミン含有組成物 |
| JPH11504028A (ja) * | 1995-04-24 | 1999-04-06 | イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム | 油／水エマルジョンを作り出す自己乳化性配合物 |
| EP0799616A1 (en) * | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| US6248354B1 (en) * | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
-
1999
- 1999-03-04 US US09/262,623 patent/US6248354B1/en not_active Expired - Fee Related
-
2000
- 2000-03-03 WO PCT/US2000/005811 patent/WO2000051571A2/en not_active Ceased
- 2000-03-03 JP JP2000602039A patent/JP2002538098A/ja active Pending
- 2000-03-03 EP EP00916109A patent/EP1158965A2/en not_active Withdrawn
- 2000-03-03 HK HK02103939.6A patent/HK1042241A1/zh unknown
- 2000-03-03 AU AU37266/00A patent/AU768796B2/en not_active Ceased
- 2000-03-03 CA CA002363933A patent/CA2363933C/en not_active Expired - Fee Related
-
2001
- 2001-01-12 US US09/760,133 patent/US6656500B2/en not_active Expired - Fee Related
-
2003
- 2003-11-21 US US10/719,287 patent/US20040115257A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4612194A (en) * | 1984-02-15 | 1986-09-16 | Roshdy Ismail | Anti-rheumatic agents and their use |
| EP0184942A2 (en) * | 1984-12-14 | 1986-06-18 | Ortho Pharmaceutical Corporation | Improved pharmaceutical composition containing 13-CIS vitamin a acid as the active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1158965A2 (en) | 2001-12-05 |
| WO2000051571A2 (en) | 2000-09-08 |
| CA2363933C (en) | 2006-07-11 |
| HK1042241A1 (zh) | 2002-08-09 |
| WO2000051571B1 (en) | 2001-05-25 |
| JP2002538098A (ja) | 2002-11-12 |
| US20010016206A1 (en) | 2001-08-23 |
| CA2363933A1 (en) | 2000-09-08 |
| WO2000051571A3 (en) | 2001-02-15 |
| AU3726600A (en) | 2000-09-21 |
| US20040115257A1 (en) | 2004-06-17 |
| US6248354B1 (en) | 2001-06-19 |
| US6656500B2 (en) | 2003-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU768796B2 (en) | Capsule system | |
| ES2592504T3 (es) | Preparaciones de liberación controlada | |
| KR100441167B1 (ko) | 마이크로에멀젼 예비 농축액 조성물 | |
| RU2121344C1 (ru) | Лекарственная форма двухфазного действия с высвобождением для липофильных лекарственных препаратов и способ ее получения | |
| EP2289496B1 (en) | Non-gelatin soft capsule system | |
| JP3678745B2 (ja) | 高濃度アセトアミノフェン溶液含有ゼラチンカプセル | |
| US5595758A (en) | Soft-shelled gelatin encapsulated particles | |
| EA006141B1 (ru) | Приготовление эмульсий витаминов и их концентратов | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| US20110033529A1 (en) | Oral pharmaceutical paricalcitol formulations | |
| CN105188670A (zh) | 乳液制剂 | |
| KR20110022586A (ko) | 인돌리논 유도체의 즉시 방출용 약제학적 투여형 | |
| EP0152292A2 (en) | Acetaminophen gelatin capsules | |
| MX2009000145A (es) | Capsulas duras llenas con liquido que contiene ibuprofeno. | |
| WO2018112119A1 (en) | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations | |
| US6383515B2 (en) | Solvent system for enhancing solubility | |
| EP1005346A2 (en) | Solutions containing azasteroids | |
| KR20010032320A (ko) | 용해된 파록세틴을 포함하는 제형 | |
| EP2976068A1 (en) | Pharmaceutical compositions comprising an active agent | |
| US8486445B2 (en) | Self-microemulsifying mitotane composition | |
| US12599568B2 (en) | Softgel capsules having a fill composition comprising magnesium oxide | |
| EP2949319A1 (en) | Pharmaceutical compositions comprising an active agent | |
| Riyaz et al. | SELF EMULSIFING DRUG DELIVERY SYSTEM (SEDDS)-A REVIEW | |
| Hutchison | Encapsulation in Softgels for Pharmaceutical Advantage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ALLERGAN, INC Free format text: THE FORMER OWNER WAS: ALLERGAN SALES, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |